Ifinatamab Deruxtecan Shows Promising Activity in Previously Treated Extensive‑Stage SCLC: Primary Analysis of Phase II IDeate‑Lung01
Posted innews Oncology

Ifinatamab Deruxtecan Shows Promising Activity in Previously Treated Extensive‑Stage SCLC: Primary Analysis of Phase II IDeate‑Lung01

In the phase II IDeate‑Lung01 trial, ifinatamab deruxtecan (I‑DXd) at 12 mg/kg every 3 weeks produced a confirmed ORR of 48.2% and median PFS 4.9 months in heavily pretreated extensive‑stage small cell lung cancer (ES‑SCLC), with an adjudicated treatment‑related ILD rate of 12.4%. Results support further development with careful ILD monitoring.